NASDAQ:AEZS
AEterna Zentaris Inc. Stock News
$1.95
-0.0100 (-0.510%)
At Close: Apr 16, 2024
- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of m acimorelin for th
Aeterna Zentaris Starts Research Study On How Well Macimorelin Works For Growth Hormone Deficiency Diagnosis
09:33am, Thursday, 13'th May 2021
Aeterna Zentaris Inc (NASDAQ: AEZS) has commenced its pivotal Phase 3 DETECT trial evaluating macimorelin as a diagnosis of childhood-onset growth hormone deficiency (CGHD). The investigational n
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
08:05am, Thursday, 13'th May 2021
– Safety and efficacy study for macimorelin initiated as agreed with U . S . FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP")
Aeterna Zentaris to Present at the Q2 Virtual Investor Summit
08:05am, Monday, 10'th May 2021
– Live video webcast with CEO, Dr. Klaus Paulini, on Monday, May 17, 2021 at 8:45 AM ET
Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
04:35pm, Wednesday, 05'th May 2021
CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercia
Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates
08:05am, Wednesday, 05'th May 2021
– Q1 2021 marked by solid operational execution with expansion and diversification of pipeline , intellectual property and portfolio of assets
Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer
08:05am, Monday, 03'rd May 2021
– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncology
Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders
08:05am, Wednesday, 28'th Apr 2021
CHARLESTON, S.C., April 28, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and de
3 Penny Stocks to Watch During the Last Week of April
09:33am, Monday, 26'th Apr 2021
As April comes to an end, are these 3 penny stocks worth watching? The post 3 Penny Stocks to Watch During the Last Week of April appeared first on Penny Stocks to Buy, Picks, News and Information | P
Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results
08:05am, Thursday, 25'th Mar 2021
– Company executing on growth strategy to build-out pipeline of development assets
Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement
04:05pm, Monday, 22'nd Mar 2021
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and de
AEZS Stock: Why Aeterna Zentaris Shares Are Shooting Higher Today
02:10pm, Monday, 15'th Mar 2021
Investors in AEZS stock have continued to pile into this trade today, with the stock up more than 40% on news around its Covid-19 vaccine. The post AEZS Stock: Why Aeterna Zentaris Shares Are Shooting
AEZS Stock Price Increases Over 10% Pre-Market: Why It Happened
08:53am, Monday, 15'th Mar 2021
The stock price of AEterna Zentaris Inc. (NASDAQ: AEZS) increased by over 10% pre-market. This is why it happened.
- Company secures next step to continue to build-out pipeline of assets